CereVasc, Inc. is developing the eShunt® System for the treatment of patients with communicating hydrocephalus, one of the most common neurological conditions affecting both children and adults. Current treatment of these patients requires an invasive, neurosurgical procedure with a documented rate of success well below the success rate for other neurosurgical interventions. The eShunt System has the potential to significantly improve patient outcomes and substantially decrease the overall cost of surgical treatment of this life-threatening condition.
Product & Services Information
The eShunt® System is a new, investigational device for the treatment of NPH. The procedure to implant the shunt is minimally invasive, meaning it can be done with only a small incision in the leg.Currently, NPH is treated with traditional shunts, including the ventriculoperitoneal (VP) shunt. Traditional shunts come with certain challenges, including increased risk of infection, shunt failure, and other complications that can lead to multiple follow-up visits and more surgeries. The US Food and Drug Administration has granted the eShunt® System a Breakthrough Device Designation. This program recognizes certain medical devices that may provide more effective treatments for serious conditions.
